SS Innovations Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

SS Innovations International, Inc. (NASDAQ: SSII) provided an update on the continued expansion and utilization of its SSi Mantra surgical robotic system, reporting 14,103 cumulative procedures as of Sept. 8, 2026, up 79% from 7,885 at year-end 2025. The company's installed base increased 42% to 238 systems from 168, reflecting growing adoption of its affordable robotic surgery platform. These figures underscore the company's momentum in a market long dominated by expensive, less accessible systems, and suggest that its strategy to democratize robotic surgery is gaining traction.

The SSi Mantra is now installed across 12 countries, with approximately 1,500 physicians trained on the platform and more than 170 types of surgical procedures performed. Recent international milestones include the launch of robotic cardiac surgery in Colombia, installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments signal that SS Innovations is successfully penetrating diverse healthcare markets, including emerging economies where cost-effective solutions are critical. The ability to perform complex cardiac procedures robotically in Colombia, for instance, demonstrates the system's versatility and potential to address unmet surgical needs globally.

SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such achievements illustrate the platform's reliability and efficiency, and they position the company as a leader in telesurgery—a field with profound implications for extending specialized surgical care to remote or underserved regions. The high-volume, single-day procedures further validate the system's capacity to support busy surgical practices without compromising outcomes.

Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal: FDA clearance would open the largest medical device market in the world, while CE marking would grant access to the European Economic Area. Success in these jurisdictions could dramatically accelerate revenue growth and further validate the technology on a global scale. For investors, the timeline provides clear catalysts to watch, and the company's progress to date suggests it is well-positioned to meet them.

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. For more information, visit the full report. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.